Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

C. Turner, Nicholas; J. Slamon, Dennis; Ro, Jungsil; Bondarenko, Igor; Im, Seock‐Ah; Masuda, Norikazu; Colleoni, Marco; DeMichele, Angela; Loi, Sherene; Verma, Sunil; Iwata, Hiroji; Harbeck, Nadia; Loibl, Sibylle; André, Fabrice; Puyana Theall, Kathy; Huang, Xin; Giorgetti, C.; Huang Bartlett, Cynthia; Cristofanilli, Massimo

doi:10.1056/nejmoa1810527

Public

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

Published in New England Journal of Medicine • Oct 20, 2018

Authors:

Nicholas C. Turner

Dennis J. Slamon

Jungsil Ro

Abstract

BACKGROUND: The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib, in combination with fulvestrant therapy, prolongs progression-free survival among patients with hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. We report the re...

Subject

Fulvestrant

Palbociclib

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!